NASDAQ:ANIX

Anixa Biosciences Q1 2026 Earnings Results & Report

Anixa Biosciences logo
$2.44 -0.16 (-6.15%)
As of 04:00 PM Eastern

Anixa Biosciences beat analyst earnings expectations in its Q1 2026 results, released March 9, 2026. The company reported EPS of -$0.08 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Anixa Biosciences EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Anixa Biosciences' Q4 2026 earnings is estimated for Monday, January 11, 2027, based on past reporting schedules, with a conference call scheduled on Tuesday, January 12, 2027 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Anixa Biosciences Q1 2026 Earnings FAQ

Anixa Biosciences (NASDAQ:ANIX) reported earnings of -$0.08 per share for Q1 2026, beating the consensus estimate of -$0.09. The report was announced on Monday, March 9, 2026.

Anixa Biosciences' next earnings date is estimated for Monday, January 11, 2027. MarketBeat tracks confirmed and estimated earnings dates for Anixa Biosciences on the company's earnings history page.

Anixa Biosciences Earnings Headlines

Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners.

The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets.

Anixa has also pursued cancer-detection technologies through its Cchek platform. The company is led by Amit Kumar, who serves as chairman and chief executive officer.

View Anixa Biosciences Profile